Cholesterol-Lowering Drugs Market Forecast 2015-2025 : Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists

コレステロール低下剤の世界市場:PCSK9阻害薬、CETP阻害薬、MTTP阻害薬、ApoB阻害薬、PPARアゴニスト

◆タイトル:Cholesterol-Lowering Drugs Market Forecast 2015-2025 : Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists
◆商品コード:VGAIN5112512
◆調査・発行会社:visiongain
◆発行日:2015年11月
◆ページ数:199
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥273,448見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥455,848見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥759,848見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、コレステロール低下剤の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・コレステロール低下剤の世界市場
 (市場規模予測、市場の成長要因・阻害要因など)
・コレステロール低下剤の世界市場:製品別市場分析
 (PCSK9阻害薬、CETP阻害薬、MTTP阻害薬、ApoB阻害薬、PPARアゴニスト)
・コレステロール低下剤の世界市場:専門家の見解
・コレステロール低下剤の世界市場:主要企業分析
・結論

What can be expected from the cholesterol-lowering drugs market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.

Our 199-page report provides 153 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications
How will submarkets perform to 2025? Our study forecasts revenues in the following cholesterol-lowering drugs submarkets and products:
• Statins and Fixed-Dose Combinations
- Crestor
- Lipitor
- Livalo
- Lescol/Lescol XL
- Zocor
- Vytorin
- Caduet
- Other Statins and Fixed-Dose Combinations (grouped forecast)
• Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs
- Zetia
- Welchol
- Tricor
- Other cholesterol-lowering drugs (grouped forecast)
• PCSK9 Inhibitors
- Praluent
- Repatha
- RN316
- Other PCSK9 Inhibitors (grouped forecast)
• Novel Cholesterol-Lowering Drugs
- Juxtapid
- Kynamro
- MK-0859
- Other novel cholesterol-lowering drugs (grouped forecast)

See revenue forecasts for the leading international markets
How will leading national markets perform to 2025? Our study forecasts revenues in national markets including products, including:
• US
• Japan
• Germany
• France
• Italy
• Spain
• UK
• China
• Brazil
• Russia
• India

Leading companies and potential for market growth
Overall revenue for the cholesterol-lowering drugs market will reach $24.63bn in 2019, our work forecasts. We predict strong revenue growth through to 2025. Shifts in diets and lifestyles will contribute to rising levels of high cholesterol, while highly disruptive new treatments will revitalise the market

Our work analyses the key companies in the market. See visiongain’s analysis of 9 leading companies, including these:
• AstraZeneca
• Merck
• Pfizer
• Kowa
• Daiichi Sankyo
• Abbvie
• Novartis
• Sanofi
• Amgen

A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Analysis of products currently on the market as well as pipeline products
• Company news relevant to the market

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect Cholesterol-Lowering Drugs industry?
Our new report discusses issues and events affecting the cholesterol-lowering drugs market. You will find discussions, including qualitative analyses:
• Highly disruptive treatments entering the market
• Increasing potential in both established and emerging markets

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Cholesterol-Lowering Drugs Market Forecast 2015-2025 report helps you
In summary, our 199-page report gives you the following knowledge:
• Revenue forecasts to 2025 for the Cholesterol-Lowering Drugs market – discover the industry’s prospects, finding promising places for investments and revenues
• Revenue forecasts to 2025 for submarkets in each – statins and fixed-dose combinations, absorption inhibitors, ion-exchange resins fibrates, PCSK9 inhibitors and novel drugs
• Revenue forecasts to 2025 for the leading regional markets – US, Japan, EU5 and BRIC
• Assessment of 9 leading companies – analysis of cholesterol-lowering products, revenue, news and upcoming product releases
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

【レポートの目次】

1. Report Overview
1.1 Global Cholesterol-Lowering Drugs Market Overview
1.2 Global Cholesterol-Lowering Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Cholesterol-Lowering Drugs
2.1 The Pharmaceutical Industry: A Brief Overview
2.2 Cholesterol: An Essential Lipid
2.3 The Functions of Cholesterol
2.4 Metabolism and Circulation of Cholesterol
2.5 The Role of Cholesterol in Heart Disease
2.6 The Role of Cholesterol in Heart Disease: The Orthodoxy
2.6.1 The IMPROVE-IT Study
2.7 The Role of Cholesterol in Heart Disease: The Controversy
2.8 Raising HDL Cholesterol: A Worthwhile Aim?
2.9 Causes of Hypercholesterolaemia
2.9.1 Atherosclerosis
2.9.2 Dyslipidaemia, Hyperlipidaemia and Hyperlipoproteinaemia
2.9.3 Familial Hypercholesterolaemia
2.10 Treatment of Hypercholesterolaemia
2.10.1 UK Treatment Guidelines for Hypercholesterolaemia
2.10.2 US Treatment Guidelines for Hypercholesterolaemia
2.10.3 Lifestyle Changes
2.10.4 Drugs to Lower Cholesterol
2.10.5 Other Therapeutic Approaches
2.10.5.1 Partial Ileal Bypass: An Outdated Surgical Treatment
2.10.5.2 LDL Apheresis: Directly Removing Cholesterol
2.10.5.3 Liver Transplantation for Familial Hypercholesterolaemia
2.11 Classification of Cholesterol-Lowering Drugs
2.11.1 Statins
2.11.2 Selective Cholesterol Absorption Inhibitors
2.11.3 Ion Exchange Resins
2.11.4 Fibrates
2.11.5 Other Cholesterol-Lowering Drugs
2.11.6 Novel Cholesterol-Lowering Drugs
2.11.7 PCSK9 Inhibitors
2.12 Phases of Clinical Trials
2.13 Scope of This Report
2.13.1 Products Excluded from This Report
2.14 Currency Exchange Rates in This Report

3. Cholesterol-Lowering Drugs: World Market 2015-2025
3.1 The World Cholesterol-Lowering Drugs Market in 2014
3.1.1 Leading Cholesterol-Lowering Drugs Products
3.1.2 Leading Companies in the Cholesterol-Lowering Drugs Market
3.2 World Cholesterol-Lowering Drugs Market: Sales Forecast 2015-2025
3.3 Cholesterol-Lowering Drugs Market Segments: Sales Forecasts 2015-2025
3.3.1 Cholesterol-Lowering Drugs Market Segmentation
3.4 Changing Market Shares by Segment 2015-2025
3.4.1 World Cholesterol-Lowering Drugs Market: Drivers and Restraints 2015-2025

4. Leading National Markets, 2015-2025
4.1 Regional Breakdown of the World Cholesterol-Lowering Drugs Market
4.1.1 World Cholesterol-Lowering Drugs Market: Regional Forecast 2015-2025
4.1.2 How Will Regional Market Shares Change to 2025?
4.2 National Breakdown of the World Cholesterol-Lowering Drugs Market
4.2.1 World Cholesterol-Lowering Drugs Market: National Markets Forecast 2015-2025
4.2.2 How Will National Market Shares Change to 2025?
4.3 The US Cholesterol-Lowering Drugs Market 2015-2025
4.3.1 US Cholesterol-Lowering Drug Market Forecast 2015-2025
4.3.2 US Cholesterol-Lowering Drugs Market: Drivers and Restraints
4.3.2.1 High Prevalence of High Cholesterol in US
4.4 The Cholesterol-Lowering Drugs Market in the Five Leading European National Markets to 2025
4.4.1 EU5 Cholesterol-Lowering Drugs Market: Drivers and Restraints
4.4.2 The Cholesterol-Lowering Drugs Market in Germany to 2025
4.4.2.1 German Cholesterol-Lowering Drugs Market: Trends and Developments
4.4.3 The Cholesterol-Lowering Drugs Market in France to 2025
4.4.3.1 French Cholesterol-Lowering Drugs Market: Trends and Developments
4.4.4 The Cholesterol-Lowering Drugs Market in the UK to 2025
4.4.4.1 UK Cholesterol-Lowering Drugs Market: Trends and Developments
4.4.5 The Cholesterol-Lowering Drugs Market in Italy to 2025
4.4.5.1 Italian Cholesterol-Lowering Drugs Market: Trends and Developments
4.4.6 The Cholesterol-Lowering Drugs Market in Spain to 2025
4.4.6.1 Spanish Cholesterol-Lowering Drugs Market: Trends and Developments
4.5 The Cholesterol-Lowering Drugs Market in the BRIC National Markets to 2025
4.5.1 BRIC Cholesterol-Lowering Drugs Market: Drivers and Restraints
4.5.2 The Cholesterol-Lowering Drugs Market in China to 2025
4.5.2.1 Chinese Cholesterol-Lowering Drugs Market: Trends and Developments
4.5.2.1.1 Economic Challenges
4.5.2.1.2 Expansion of Healthcare Coverage and Reimbursement
4.5.3 The Cholesterol-Lowering Drugs Market in Brazil to 2025
4.5.3.1 Brazilian Cholesterol-Lowering Drugs Market: Trends and Developments
4.5.4 The Cholesterol-Lowering Drugs Market in Russia to 2025
4.5.4.1 Russian Cholesterol-Lowering Drugs Market: Trends and Developments
4.5.4.1.1 Lower Oil Prices
4.5.4.1.2 No Embargo on Foreign Drugs
4.5.5 The Cholesterol-Lowering Drugs Market in India to 2025
4.5.5.1 Indian Cholesterol-Lowering Drugs Market: Trends and Developments
4.5.5.1.1 Drug Price Control Order 2014
4.5.5.1.2 Expansion of Healthcare Provision
4.6 The Cholesterol-Lowering Drugs Market in Japan to 2025
4.6.1 Japanese Cholesterol-Lowering Drugs Market: Trends and Developments
4.6.1.1 Generic Penetration to Reach 60% by 2018?
4.6.1.2 Japanese Pharmaceutical Industry Regulatory Reform

5. Statins and Fixed-Dose Combinations: Market and Pipeline 2015-2025
5.1 Statins: Inhibiting HMG-CoA Reductase
5.2 The Statins and Fixed-Dose Combinations Market in 2014
5.3 Statins and Fixed-Dose Combinations: Market Forecast 2015-2025
5.4 How Will Market Shares of Products Change to 2025?
5.5 Crestor (Rosuvastatin, AstraZeneca)
5.5.1 Crestor: Historical Sales Estimate 2009-2014
5.5.2 Crestor: Sales Forecast 2015-2025
5.5.3 Generic Competition for Crestor
5.6 Lipitor (Atorvastatin, Pfizer)
5.6.1 Lipitor: Historical Sales Estimate 2009-2014
5.6.2 Lipitor: Sales Forecast 2015-2025
5.7 Livalo (Pitavastatin, Kowa)
5.7.1 Livalo: Sales Forecast 2015-2025
5.8 Lescol and Lescol XL (Fluvastatin, Novartis)
5.8.1 Lescol/Lescol XL: Sales Forecast 2015-2025
5.9 Zocor (Simvastatin, Merck)
5.9.1 Zocor: Sales Forecast 2015-2025
5.10 Fixed-Dose Combinations
5.11 Vytorin (Simvastatin/Ezetimibe, Merck)
5.11.1 Vytorin: Sales Forecast 2015-2025
5.12 Caduet (Atorvastatin/Amlodipine, Pfizer)
5.12.1 Caduet: Sales Forecast 2015-2025

6. Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Market and Pipeline 2015-2025
6.1 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Overview
6.2 The Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market in 2014
6.3 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Market Forecast 2015-2025
6.4 How Will Market Shares of Products Change to 2025?
6.5 Zetia (Ezetimibe, Merck)
6.5.1 The ENHANCE Study: No Additional Benefit
6.5.2 The IMPROVE-IT Study: Reduction in Cardiovascular Risk
6.5.3 Zetia: Sales Forecast 2015-2025
6.6 Welchol (Colesevelam, Daiichi Sankyo)
6.6.1 Threat of Imminent Generic Competition for Welchol
6.6.2 Welchol: Sales Forecast 2015-2025
6.7 Tricor (Fenofibrate, AbbVie)
6.7.1 Generic Erosion of Tricor Sales
6.7.2 Tricor: Sales Forecast 2015-2025

7. PCSK9 Inhibitors: Market and Pipeline 2015-2025
7.1 PCSK9 Inhibitors: The Next Blockbuster Drug Class?
7.2 PCSK9 in Clinical Trials
7.3 PCSK9 Inhibitors and Statins
7.4 PCSK9 Inhibitors: Market Forecast 2015-2025
7.5 How Will Market Shares of Products Change to 2025?
7.6 PCSK9 Inhibitors: Pipeline Analysis 2015-2025
7.7 Praluent (Alirocumab, Sanofi/Regeneron)
7.7.1 Praluent: Sales Forecast 2015-2025
7.8 Repatha (Evolocumab, Amgen)
7.8.1 GAUSS-2
7.8.2 RUTHERFORD-2
7.8.3 LAPLACE-2
7.8.4 Repatha: Sales Forecast 2015-2025
7.9 RN316 (Bococizumab, Pfizer)
7.9.1 RN316: Sales Forecast 2015-2025
7.10 Oral PCSK9 Inhibitor (Pfizer)
7.11 PF-06427878 (Pfizer)
7.12 PCSK9 Vaccine (Pfizer)
7.13 SX-PCK9 (Serometrix)
7.14 Discontinued Pipeline Products
7.14.1 BMS-962476 (Adnectin, Bristol-Myers Squibb)
7.14.2 LY3015014 (Eli Lilly)

8. Novel Cholesterol-Lowering Drugs: Market and Pipeline 2015-2025
8.1 Novel Cholesterol-Lowering Drugs: Overview
8.2 Novel Cholesterol-Lowering Drugs Market in 2014
8.3 Novel Cholesterol-Lowering Drugs: Market Forecast 2015-2025
8.4 How Will Market Shares of Products Change to 2025?
8.5 CETP Inhibitors: Overview
8.5.1 CETP Inhibitors: Pipeline Analysis 2015-2025
8.5.2 MK-0859 (Anacetrapib, Merck)
8.5.2.1 MK-0859 (Anacetrapib): Sales Forecast 2015-2025
8.5.3 Dalcetrapib (DalCor)
8.5.4 DEZ-001/TA-8995 (CETP Inhibitor, Dezima/Amgen)
8.5.5 DRL-17822 (CETP Inhibitor, Dr. Reddy’s Laboratories)
8.5.6 PRC-4016 (Icosabutate, ProNova BioPharma)
8.5.7 K-312 (CETP Inhibitor, Kowa)
8.6 MTTP Inhibitors: Market and Pipeline Analysis 2015-2025
8.6.1 Juxtapid (Lomitapide, Aegerion Pharmaceuticals)
8.6.1.1 Juxtapid (Lomitapide): Sales Forecast 2015-2025
8.7 ApoB Inhibitors: Market and Pipeline Analysis 2015-2025
8.7.1 Kynamro (Mipomersen, Isis Pharmaceuticals/Sanofi)
8.7.1.1 Kynamro (Mipomersen): Drug Launch and Pricing Strategy
8.7.1.2 Kynamro (Mipomersen): Sales Forecast 2015-2025
8.8 Other Drug Classes: Market and Pipeline Analysis 2015-2025
8.8.1 K-877 (PPAR-α Agonist, Kowa)
8.8.2 REGN1500 (ANGPTL3 Inhibitor, Regeneron)
8.8.3 ETC-1002 (ACL Inhibitor, Esperion Therapeutics)
8.8.4 ALN-PCS02 and ALN-PCSsc (Alnylam)
8.9 Discontinued Pipeline Products
8.9.1 Torcetrapib
8.9.2 LY2484595 (Evacetrapib)

9. Leading Companies in the Cholesterol-Lowering Drugs Market
9.1 Leading Cholesterol-Lowering Drugs Manufacturers in 2014
9.1.1 Leading Companies: Market Forecast 2015-2025
9.1.2 How Will Leading Companies’ Market Shares Change to 2025?
9.2 AstraZeneca
9.2.1 AstraZeneca: Cholesterol-Lowering Drugs
9.2.2 AstraZeneca: Sales Forecast 2015-2025
9.2.3 AstraZeneca: Recent Developments
9.2.3.1 Cholesterol Awareness Initiative in America
9.2.3.2 AstraZeneca Rejects Pfizer Takeover Bid
9.3 Merck
9.3.1 Merck: Cholesterol-Lowering Drugs
9.3.2 Merck: Sales Forecast 2015-2025
9.3.3 Merck: Recent Developments
9.3.3.1 Bayer Acquires Merck’s Consumer Health Business
9.3.3.2 Study Shows Lower LDL Levels Are More Beneficial
9.4 Pfizer
9.4.1 Pfizer: Cholesterol-Lowering Drugs
9.4.2 Pfizer: Sales Forecast 2015-2025
9.4.3 Pfizer: Recent Developments
9.4.3.1 Pfizer Ends Over-The-Counter Lipitor Program
9.4.3.2 Development of Oral PCSK9 Inhibitor
9.5 Kowa
9.5.1 Kowa: Cholesterol-Lowering Drugs
9.5.2 Kowa: Sales Forecast 2015-2025
9.5.3 Kowa: Recent Developments
9.5.3.1 Development of K-312
9.5.3.2 Development of K-887
9.6 Daiichi Sankyo
9.6.1 Daiichi Sankyo: Cholesterol-Lowering Drugs
9.6.2 Daiichi Sankyo: Sales Forecast 2015-2025
9.6.3 Daiichi Sankyo: Recent Developments
9.6.3.1 Staff Reduction at US Operation
9.7 AbbVie
9.7.1 AbbVie: Cholesterol-Lowering Drugs
9.7.2 AbbVie: Sales Forecast 2015-2025
9.7.3 AbbVie: Recent Developments
9.7.3.1 Possible Marketing Cost Reductions
9.8 Novartis
9.8.1 Novartis: Cholesterol-Lowering Drugs
9.8.2 Novartis: Sales Forecast 2015-2025
9.9 Sanofi
9.9.1 Sanofi: Cholesterol-Lowering Drugs
9.9.2 Sanofi: Sales Forecast 2015-2025
9.9.3 Sanofi: Recent Developments
9.9.3.1 Purchase of Priority Review Voucher from BioMarin Pharmaceuticals
9.10 Amgen
9.10.1 Amgen: Cholesterol-Lowering Drugs
9.10.2 Amgen: Sales Forecast 2015-2025
9.10.3 Amgen: Recent Developments
9.10.3.1 Amgen Sues Sanofi and Regeneron To Block Praluent

10. Qualitative Analysis of the Cholesterol-Lowering Drugs Market 2015-2025
10.1 SWOT Analysis of the Cholesterol-Lowering Drugs Market
10.2 Strengths
10.2.1 Strong Pipeline
10.2.2 High Profile Encouraging Healthcare Provision
10.3 Weaknesses
10.3.1 Increasing Generic Penetration
10.3.2 Approved Indications Limited for New Products
10.4 Opportunities
10.4.1 Increasing Prevalence in Emerging Markets
10.4.2 Possible Additional Indications
10.5 Threats
10.5.1 Patent Expiry
10.5.2 Cost-Containment
10.6 Porter’s Five Forces Analysis of the Cholesterol-Lowering Drugs Market
10.6.1 Rivalry among Competitors [High]
10.6.2 Threat of New Entrants [Medium]
10.6.3 Power of Suppliers [Low]
10.6.4 Power of Buyers [Medium]
10.6.5 Threat of Substitutes [High]

11. Conclusions
11.1 The World Cholesterol-Lowering Drugs Market: 2014-2015
11.2 The World Cholesterol-Lowering Drugs Market Forecast: 2014-2025

12. Glossary

List of Tables
Table 1.1 Leading National Cholesterol-Lowering Drugs Market Forecast 2015 ($m, AGR%)
Table 2.1 Clinical Trial Phases
Table 2.2 Currency Exchange Rates, 2014
Table 3.1 Top 10 Cholesterol-Lowering Drugs: Revenue ($m) and Market Share (%), 2014
Table 3.2 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 3.3 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Drug Class, 2014-2025
Table 3.4 Market Shares (%) of Cholesterol-Lowering Drug Market Segments, 2014, 2019 and 2025
Table 4.1 World Cholesterol-Lowering Drugs Market: Revenues ($m) and Market Shares (%) by Region, 2014
Table 4.2 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Region, 2014-2025
Table 4.3 Market Shares (%) of Leading Cholesterol-Lowering Drugs Market, 2014, 2019 and 2025
Table 4.4 World Cholesterol-Lowering Drugs Market: Revenues ($m), and Market Shares (%) by National Market, 2014
Table 4.5 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by National Market, 2014-2025
Table 4.6 World Cholesterol-Lowering Drugs Market: Market Shares (%) by National Market, 2014
Table 4.7 US Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.8 EU5 Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.9 German Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.10 French Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.11 UK Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.12 Italian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.13 Spanish Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.14 BRIC Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.15 Chinese Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.16 Brazilian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.17 Russian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.18 Indian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 4.19 Japanese Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
Table 5.1 Leading Statins and Fixed-Dose Combinations: Revenue ($m) and Market Shares (%), 2014
Table 5.2 Statins and Fixed-Dose Combinations Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.3 Statins and Fixed-Dose Combinations Market: Market Shares (%) by Drug, 2014, 2019 and 2025
Table 5.4 AstraZeneca/Shionogi: Crestor Revenue ($m), AGR (%) and CAGR (%), 2009-2014
Table 5.5 AstraZeneca/Shionogi: Crestor Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.6 Pfizer: Lipitor Revenue ($m), AGR (%) and CAGR (%), 2009-2014
Table 5.7 Pfizer: Lipitor Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.8 Kowa: Livalo Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.9 Novartis: Lescol/Lescol XL Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.10 Merck: Zocor Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.11 Merck: Vytorin Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.12 Pfizer: Caduet Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 6.1 Leading Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Revenue ($m) and Market Shares (%), 2014
Table 6.2 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
Table 6.3 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market: Market Shares (%) by Drug, 2014, 2019 and 2025
Table 6.4 Merck: Zetia Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 6.5 Daiichi Sankyo: Welchol Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 6.6 AbbVie: Tricor Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 7.1 PCSK9 Inhibitors Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
Table 7.2 PCSK9 Inhibitors Market: Market Shares (%) by Drug, 2015, 2019 and 2025
Table 7.3 Sanofi/Regeneron: Praluent Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 7.4 Amgen: Repatha Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 7.5 Pfizer: RN316 (Bococizumab) Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 8.1 Novel Cholesterol-Lowering Drugs: Revenue ($m) and Market Shares (%), 2014
Table 8.2 Novel Cholesterol-Lowering Drugs Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
Table 8.3 Novel Cholesterol-Lowering Drugs Market: Market Shares (%) by Drug, 2014, 2019 and 2025
Table 8.4 Merck: MK-0859 (Anacetrapib) Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 8.5 Aegerion Pharmaceuticals: Juxtapid (Lomitapide) Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 8.6 Isis Pharmaceuticals/Sanofi: Kynamro (Mipomersen) Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 9.1 Leading Cholesterol-Lowering Drugs Manufacturers: Cholesterol-Lowering Drugs Revenue ($m), Market Share (%), 2014
Table 9.2 Leading Cholesterol-Lowering Drug Manufacturers: Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 9.3 Leading Cholesterol-Lowering Drug Manufacturers: Revenue ($m) and Market Shares (%), 2019 and 2025
Table 9.4 AstraZeneca: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025
Table 9.5 Merck: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025
Table 9.6 Pfizer: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025
Table 9.7 Kowa: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025
Table 9.8 Daiichi Sankyo: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025
Table 9.9 AbbVie: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025
Table 9.10 Novartis: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025
Table 9.11 Sanofi: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025
Table 9.12 Amgen: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025
Table 10.1 SWOT Analysis of the Cholesterol-Lowering Drugs Market, 2015-2025
Table 11.1 World Cholesterol-Lowering Drug Market Regions: Revenues ($m), 2014 and 2015
Table 11.2 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2025

List of Figures
Figure 1.1 Global Cholesterol-Lowering Drugs Market Segmentation Overview, 2015
Figure 2.1 Chemical Structure of Cholesterol, 2015
Figure 3.1 Top 10 Cholesterol-Lowering Drugs: Market Share (%), 2014
Figure 3.2 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m) and AGR (%), 2014-2025
Figure 3.3 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m) by Drug Class, 2014-2025
Figure 3.4 Market Shares (%) of Cholesterol-Lowering Drug Market Segments, 2019
Figure 3.5 Market Shares (%) of Cholesterol-Lowering Drug Market Segments, 2025
Figure 3.6 Global Cholesterol-Lowering Drugs Market: Drivers and Restraints, 2015-2025
Figure 4.1 World Cholesterol-Lowering Drugs Market: Revenues ($m) by Region, 2014
Figure 4.2 World Cholesterol-Lowering Drugs Market: Market Shares (%) by Region, 2014
Figure 4.3 World Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) by Region, 2014-2025
Figure 4.4 World Cholesterol-Lowering Drugs Market: Market Shares (%) by Region, 2019
Figure 4.5 World Cholesterol-Lowering Drugs Market: Market Shares (%) by Region, 2025
Figure 4.6 World Cholesterol-Lowering Drugs Market: Revenues ($m) by National Market, 2014
Figure 4.7 World Cholesterol-Lowering Drugs Market: Market Shares (%) by National Market, 2014
Figure 4.8 World Cholesterol-Lowering Drugs Market: Market Shares (%) by National Market, 2019
Figure 4.9 World Cholesterol-Lowering Drugs Market: Market Shares (%) by National Market, 2025
Figure 4.10 US Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
Figure 4.11 EU5 Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
Figure 4.12 EU5 Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), 2014-2025
Figure 4.13 German Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
Figure 4.14 French Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
Figure 4.15 UK Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
Figure 4.16 Italian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
Figure 4.17 Spanish Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
Figure 4.18 BRIC Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
Figure 4.19 BRIC Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), 2014-2025
Figure 4.20 Chinese Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
Figure 4.21 Brazilian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
Figure 4.22 Russia Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
Figure 4.23 Indian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
Figure 4.24 Japanese Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
Figure 5.1 Statins and Fixed-Dose Combinations Market: Market Shares (%), 2014
Figure 5.2 Statins and Fixed-Dose Combinations Market Forecast: Revenue ($m) and AGR (%), 2014-2025
Figure 5.3 Statins and Fixed-Dose Combinations Market: Market Shares (%), 2019
Figure 5.4 Statins and Fixed-Dose Combinations Market: Market Shares (%), 2025
Figure 5.5 AstraZeneca/Shionogi: Crestor Revenue ($m) and AGR (%), 2009-2014
Figure 5.6 AstraZeneca/Shionogi: Crestor Revenue ($m) and AGR (%), 2014-2025
Figure 5.7 Pfizer: Lipitor Revenue ($m) and AGR (%), 2009-2014
Figure 5.8 Pfizer: Lipitor Revenue ($m) and AGR (%), 2014-2025
Figure 5.9 Kowa: Livalo Revenue ($m) and AGR (%), 2014-2025
Figure 5.10 Novartis: Lescol/Lescol XL Revenue ($m) and AGR (%), 2014-2025
Figure 5.11 Merck: Zocor Revenue ($m) and AGR (%), 2014-2025
Figure 5.12 Merck: Vytorin Revenue ($m) and AGR (%), 2014-2025
Figure 5.13 Pfizer: Caduet Revenue ($m) and AGR (%), 2014-2025
Figure 6.1 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Market Shares (%), 2014
Figure 6.2 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Forecast: Revenue ($m) and AGR (%), 2014-2025
Figure 6.3 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market: Market Shares (%), 2019
Figure 6.4 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market: Market Shares (%), 2025
Figure 6.5 Merck: Zetia Revenue ($m) and AGR (%), 2014-2025
Figure 6.6 Daiichi Sankyo: Welchol Revenue ($m) and AGR (%), 2014-2025
Figure 6.7 AbbVie: Tricor Revenue ($m) and AGR (%), 2014-2025
Figure 7.1 PCSK9 Inhibitors Forecast: Revenue ($m) and AGR (%), 2014-2025
Figure 7.2 PCSK9 Inhibitors Market: Market Shares (%), 2015
Figure 7.3 PCSK9 Inhibitors Market: Market Shares (%), 2019
Figure 7.4 PCSK9 Inhibitors Market: Market Shares (%), 2025
Figure 7.5 Sanofi/Regeneron: Praluent Revenue ($m) and AGR (%), 2014-2025
Figure 7.6 Amgen: Repatha Revenue ($m) and AGR (%), 2014-2025
Figure 7.7 Pfizer: RN316 (Bococizumab) Revenue ($m) and AGR (%), 2014-2025
Figure 8.1 Novel Cholesterol-Lowering Drugs: Market Shares (%), 2014
Figure 8.2 Novel Cholesterol-Lowering Drugs Forecast: Revenue ($m) and AGR (%), 2014-2025
Figure 8.3 Novel Cholesterol-Lowering Drugs Market: Market Shares (%), 2019
Figure 8.4 Novel Cholesterol-Lowering Drugs Market: Market Shares (%), 2025
Figure 8.5 Merck: MK-0859 (Anacetrapib) Revenue ($m) and AGR (%), 2014-2025
Figure 8.6 Aegerion Pharmaceuticals: Juxtapid (Lomitapide) Revenue ($m) and AGR (%), 2014-2025
Figure 8.7 Isis Pharmaceuticals/Sanofi: Kynamro (Mipomersen) Revenue ($m) and AGR (%), 2014-2025
Figure 9.1 Leading Cholesterol-Lowering Drug Manufacturers: Revenue ($m), 2014
Figure 9.2 Leading Cholesterol-Lowering Drug Manufacturers: Market Shares (%), 2014
Figure 9.3 Leading Cholesterol-Lowering Drug Manufacturers: Revenues ($m), 2019
Figure 9.4 Leading Cholesterol-Lowering Drug Manufacturers: Market Shares (%), 2019
Figure 9.5 Leading Cholesterol-Lowering Drug Manufacturers: Revenues ($m), 2025
Figure 9.6 Leading Cholesterol-Lowering Drug Manufacturers: Market Shares (%), 2025
Figure 9.7 AstraZeneca: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025
Figure 9.8 Merck: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025
Figure 9.9 Pfizer: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025
Figure 9.10 Kowa: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025
Figure 9.11 Daiichi Sankyo: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025
Figure 9.12 AbbVie: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025
Figure 9.13 Novartis: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025
Figure 9.14 Sanofi: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025
Figure 9.15 Amgen: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025
Figure 10.1 Porter’s Five Forces Analysis of the Cholesterol-Lowering Drugs Market, 2015-2025
Figure 11.1 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), by Segment, 2014-2025

【レポートのキーワード】

コレステロール低下剤、コレステロール低下薬、PCSK9阻害薬、CETP阻害薬、MTTP阻害薬、ApoB阻害薬、PPARアゴニスト、医薬品、コレステロール治療

★調査レポート[コレステロール低下剤の世界市場:PCSK9阻害薬、CETP阻害薬、MTTP阻害薬、ApoB阻害薬、PPARアゴニスト] ( Cholesterol-Lowering Drugs Market Forecast 2015-2025 : Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists / VGAIN5112512) 販売に関する免責事項
[コレステロール低下剤の世界市場:PCSK9阻害薬、CETP阻害薬、MTTP阻害薬、ApoB阻害薬、PPARアゴニスト] ( Cholesterol-Lowering Drugs Market Forecast 2015-2025 : Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists / VGAIN5112512) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆